vTv Therapeutics Inc.

NASDAQ:VTVT

14 (USD) • At close November 4, 2024
Bedrijfsnaam vTv Therapeutics Inc.
Symbool VTVT
Munteenheid USD
Prijs 14
Beurswaarde 34,060,040
Dividendpercentage 0%
52-weken bereik 7.38 - 30.99
Industrie Biotechnology
Sector Healthcare
CEO Mr. Paul J. Sekhri M.Sc., MSc
Website https://www.vtvtherapeutics.com

An error occurred while fetching data.

Over vTv Therapeutics Inc.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor

Vergelijkbare Aandelen

ARCA biopharma, Inc. logo

ARCA biopharma, Inc.

ABIO

28.8 USD

T2 Biosystems, Inc. logo

T2 Biosystems, Inc.

TTOO

0.8 USD

Acer Therapeutics Inc. logo

Acer Therapeutics Inc.

ACER

0.9 USD

Immix Biopharma, Inc. logo

Immix Biopharma, Inc.

IMMX

1.58 USD

Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc.

AVTX

13.54 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)